The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: Systematic review

BMJ Open

Volumn 4, Issue 7, 2014, Pages

  Poku, Edith ^a   Rathbone, John ^b   Wong, Ruth ^a   Everson Hock, Emma ^a   Essat, Munira ^a   Pandor, Abdullah ^a   Wailoo, Allan ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b BOND UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB;

ADULT; ANGINA PECTORIS; ARTERIAL THROMBOEMBOLISM; BRAIN INFARCTION; CATARACT; CEREBROVASCULAR ACCIDENT; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG FATALITY; DRUG SAFETY; ENDOPHTHALMITIS; EYE DISEASE; FOLLOW UP; HUMAN; HYPERTENSION; HYPHEMA; INTRAOCULAR HYPERTENSION; MONOTHERAPY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA TEAR; RETINA VEIN OCCLUSION; REVIEW; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; UVEITIS; VISUAL IMPAIRMENT; VITREOUS BODY DETACHMENT; VITREOUS HEMORRHAGE; CONTROLLED CLINICAL TRIAL (TOPIC); EYE DISEASES; INTRAVITREAL DRUG ADMINISTRATION; OBSERVATIONAL STUDY;

ADULT; BEVACIZUMAB; CONTROLLED CLINICAL TRIALS AS TOPIC; EYE DISEASES; HUMANS; INTRAVITREAL INJECTIONS; OBSERVATIONAL STUDIES AS TOPIC;

EID: 84904463795     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005244     Document Type: Review

References (100)

1. Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England and Wales. BMC Public Health 2006;6:58.
2. Soheilian M, Garfami KH, Ramezani A, et al. Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina 2012;32:314-21.
3. Raftery J, Clegg A, Jones J, et al. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Opthalmol 2007;91:1244-6. (Pubitemid 47344908)
4. Schmucker C, Loke YK, Ehlken C, et al. Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a safety review. Br J Opthalmol 2011;95:308-17.
5. van der Reis MI, La Heij EC, De Jong-Hesse Y, et al. A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina 2011;31:1449-69.
6. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377-84. (Pubitemid 28438523)
7. Ahmadieh H, Ramezani A, Shoeibi N, et al. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483-9. (Pubitemid 351447960)
8. Cekic O, Cakir M, Yazici AT, et al. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion. Curr Eye Res 2010;35:925-9.
9. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117:1078-86.
10. Scott IU, Edwards AR, Beck RW, et al.; Diabetic Retinopathy Clinical Research Network. A phase 2 randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-7.
11. Faghihi H, Roohipoor R, Mohammadi SF, et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 2008;18:941-8.
12. Epstein DLJ, Algvere PV, von Wendt G, et al. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 2012;119:1184-9.
13. Moradian S, Faghihi H, Sadeghi B, et al. Intravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months. Graefes Arch Clin Exp Ophthalmol 2011;249:193-200.
14. Bashshur ZF, Schakal A, Hamam RN, et al. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol 2007;125:1357-61. (Pubitemid 47606600)
15. Biswas P, Sengupta S, Choudhary R, et al. Comparing ranibizumab with bevacizumab. Ophthalmology 2011 118:600-600.e2. http://www.sciencedirect.com/ science/article/pii/S0161642010011036 (accessed 10 Jun 2012).
16. Martin DF, Maguire MG, Fine SL, et al.; CATT Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
17. Ding X, Li J, Hu X, et al. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina 2011;31:838-45.
18. Gharbiya M, Giustolisi R, Allievi F, et al. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab - a randomized controlled trial. Am J Ophthalmol 2010;149:458-64.
19. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN Randomized Trial. Ophthalmology 2012;119:1399-411.
20. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-85. (Pubitemid 46829388)
21. Lim JW, Lee HK, Shin MC. Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial. Ophthalmologica 2012;227:100-6.
22. Marey HM, Ellakwa AF. Intravitreal bevacizumab alone or combined with triamcinolone acetonide as the primary treatment for diabetic macular edema. Clin Ophthalmol 2011;5:1011-16.
23. Patwardhan SD, Azad R, Shah BM, et al. Role of intravitreal bevacizumab in Eales disease with dense vitreous hemorrhage: a prospective randomized control study. Retina 2011;31:866-70.
24. Schmid-Kubista KE, Krebs I, Ansari-Shahrezaei S, et al. Comparing treatment of neovascular age-related macular degeneration with sequential intravitreal Avastin and Macugen versus intravitreal mono-therapy - a pilot study. Curr Eye Res 2011;36:958-63.
25. Shahin MM, El-Lakkany RS, Shahin MM, et al. A prospective, randomized comparison of intravitreal triamcinolone acetonide versus intravitreal bevacizumab (avastin) in diffuse diabetic macular edema. Middle East Afr J Ophthalmol 2010;17:250-3.
26. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ 2010;340:c459.
27. Yazdani S, Hendi K, Pakravan M, et al. Intravitrealbevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma 2009;18:632-7.
28. Bashshur ZF, Haddad ZA, Schakal AR, et al. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. Am J Ophthalmol 2009;148:59-65.
29. Kim KS, Jee D. Effect of the Honan intraocular pressure reducer on intraocular pressure increase following intravitreal injection using the tunneled scleral technique. Jpn J Ophthalmol 2011;55:632-7.
30. Arias L, Planas N, Prades S, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol 2008;92:1035-9.
31. Good TJ, Kimura AE, Mandava N, et al. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95:1111-14.
32. Kim JY, Park SP. Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion. Korean J Ophthalmol 2009;23:259-65.
33. Abraham-Marin ML, Cortes-Luna CF, Alvarez-Rivera G, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefes Arch Clin Exp Ophthalmol 2007;245:651-5. (Pubitemid 46951230)
34. Arevalo JF, Sanchez JG, Wu L, et al. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study. Ophthalmology 2010;117:1974-81.
35. Artunay O, Yuzbasioglu E, Rasier R, et al. Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. Eye 2009;23:2187-93.
36. Azad RV, Khan MA, Chanana B, et al. Intravitreal bevacizumab for subfoveal choroidal neovascularization secondary to age-related macular degeneration in an Indian population. Jpn J Ophthalmol 2008;52:52-6. (Pubitemid 351462226)
37. Baba T, Kubota-Taniai M, Kitahashi M, et al. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Opthalmol 2010;94:864-70.
38. Bakri SJ, Risco M, Edwards AO, et al. Bilateral simultaneous intravitreal injections in the office setting. Am J Ophthalmol 2009;148:66-9.
39. Carneiro AM, Falcao MS, Brandao EM, et al. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: one-year results. Retina 2010;30:85-92.
40. Carneiro AM, Barthelmes D, Falcao MS, et al. Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica 2011;225:211-21.
41. Chen CH, Chen YH, Wu PC, et al. Treatment of branch retinal vein occlusion induced macular edema in treatment-naive cases with a single intravitreal triamcinolone or bevacizumab injection. Chang Gung Med J 2010;33:424-35.
42. Cleary CA, Jungkim S, Ravikumar K, et al. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6-and 9-month results. Eye 2008;22:82-6.
43. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006;47:4569-78. (Pubitemid 46579387)
44. Costagliola C, Romano M, Corte MD, et al. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study. Retina 2009;29:1227-34.
45. Curtis LH, Hammill BG, Schulman KA, et al. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 2010;128:1273-79.
46. Falkenstein I, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina 2007;27:1044-7. (Pubitemid 350304005)
47. Fintak DR, Shah GK, Blinder KJ, et al. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008;28:1395-9.
48. Fong KCS, Kirkpatrick N, Mohamed Q, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clin Experiment Ophthalmol 2008;36:748-55.
49. Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol 2010;128:1523-7.
50. Fukami T, Kitahashi M, Sato E, et al. Six cases of sterile endophthalmitis developed consecutively after intravitreal injection of bevacizumab [abstract]. Nippon Ganka Gakkai Zasshi - Acta Societatis Ophthalmologicae Japonicae 2011;115:706-10.
51. Gamulescu MA, Radeck V, Lustinger B, et al. Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration. Int Ophthalmol 2010;30:261-6.
52. Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Opthalmol 2008;92:70-3.
53. Goverdhan SV, Lochhead J. Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration. Br J Opthalmol 2008;92:210-12. (Pubitemid 351224096)
54. Gower EW, Cassard S, Chu L, et al. Adverse event rates following intravitreal injection of avastin or lucentis for treating age-related macular degeneration [abstract]. Invest Ophthalmol Vis Sci 2011;129; ARVO Suppl.
55. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007;27:707-12. (Pubitemid 47051766)
56. Higashide T, Murotani E, Saito Y, et al. Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol 2012;250:603-10.
57. Hollands H, Wong J, Bruen R, et al Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007;42:807-11.
58. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009;147:94-100.
59. Inman ZD, Anderson NG. Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia. Retina 2011;31:669-72.
60. Jaissle GB, Leitritz M, Gelisken F, et al. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009;247:27-33.
61. Johnson D, Hollands H, Hollands S, et al. Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: a retrospective cohort study. Can J Ophthalmol 2010;45:239-42.
62. Jonas JB, Spandau UH, Rensch F, et al. Infectious and noninfectious endophthalmitis after intravitreal bevacizumab. J Ocul Pharmacol Ther 2007;23:240-2. (Pubitemid 46986604)
63. Jonas JB, Spandau UH, Schlichtenbrede F. Short-term complications of intravitreal injections of triamcinolone and bevacizumab. Eye 2008;22:590-1. (Pubitemid 351560425)
64. Julian K, Terrada C, Fardeau C, et al. Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results. Acta Opthalmol 2011;89:179-84.
65. Kim M, Lee P, Kim Y, et al. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema. Ophthalmologica 2011;226:138-44.
66. Kiss C, Michels S, Prager F, et al. Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 2006;26:877-81. (Pubitemid 44547439)
67. Krebs I, Lie S, Stolba U, et al. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration. Acta Opthalmol 2009;87:611-17.
68. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92:518-22. (Pubitemid 351497981)
69. Krishnan R, Goverdhan S, Lochhead J, et al. Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization. Clin Experiment Ophthalmol 2009;37:384-8.
70. Kumar A, Sehra SV, Thirumalesh MB, et al. Secondary rhegmatogenous retinal detachment following intravitreal bevacizumab in patients with vitreous hemorrhage or tractional retinal detachment secondary to Eales ' disease. Graefes Arch Clin Exp Ophthalmol 2012;250:685-90.
71. Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007;245:68-73. (Pubitemid 46766732)
72. Lima LH, Zweifel SA, Engelbert M, et al. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina 2009;29:1213-17.
73. Lommatzsch A, Heimes B, Gutfleisch M, et al. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye 2009;23:2163-8.
74. Lorenz K, Zwiener I, Mirshahi A. Subconjunctival reflux and need for paracentesis after intravitreal injection of 0.1 ml bevacizumab: comparison between 27-gauge and 30-gauge needle. Graefes Arch Clin Exp Ophthalmol 2010;248:1573-7.
75. Mason JO, White MF, Feist RM, et al. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. Retina 2008;28:564-7. (Pubitemid 351589565)
76. Manayath GJ, Narendran V, Al-Kharousi N, et al. Bevacizumab therapy for macular edema in central retinal vein occlusion: Long-term results. Oman J Ophthalmol 2009;2:73-8.
77. Rasier R, Artunay O, Yuzbasioglu E, et al. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye 2009;23:1714-18.
78. Russo V, Barone A, Conte E, et al. Bevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusion. Retina 2009;29:511-15.
79. Saeed MU, Qureshi F, Batra R, et al. Effect of reflux of drug during intravitreal anti-VEGF therapies on foveal thickness. Semin Ophthalmol 2011;26:61-3.
80. Shah CP, Garg SJ, Vander JF, et al. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology 2011;118:2028-34.
81. Sharma S, Johnson D, Abouammoh M, et al. Rate of serious adverse effects in a series of bevacizumab and ranibizumab injections. Can J Ophthalmol 2012;47:275-9.
82. Shienbaum G, Gupta OP, Fecarotta C, et al. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Am J Opthalmol 2012;153:468-73.
83. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 2008;86:372-6.
84. Shimada N, Ohno-Matsui K, Hayashi K, et al. Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization. Jpn J Ophthalmol 2011;55:378-82.
85. Sivkova N, Koleva-Georgieva D. Bevacizumab for the treatment of macular oedema in patients with diabetic retinopathy and retinal vascular occlusive disorders. Auton Autacoid Pharmacol 2010;30:144-7.
86. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Opthalmol 2011;152:686-94.
87. Song JH, Lee JJ, Lee SJ, et al. Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema. Korean J Ophthalmol 2011;25:156-60.
88. Sonmez K, Sonmez PA, Ozkan SS, et al. One-year outcomes of less frequent bevacizumab in age-related macular degeneration. Retina 2011;31:645-53.
89. Spandau UHM, Jonas JB. Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration. Am J Opthalmol 2006;142:1068-70. (Pubitemid 44853878)
90. Torres-Soriano ME, Cubas-Lorenzo V, Garcia-Aguirre G, et al. Multifocal electrophysiologic findings after intravitreal bevacizumab (avastin) treatment. Retina 2012;32:972-6.
91. Valmaggia C, Haueter I, Kloos P, et al. The treatment of choroidal neovascularizations in age-related macular degeneration using either avastin or lucentis. Klin Monbl Augenheilkd 2009;226:294-8.
92. Weinberger AWA, Thiel M, Mohammadi B, et al. Retinal pigment epithelium tears after intravitreal bevacizumab in pigment epithelium detachment. Am J Opthalmol 2007;144:294-6. (Pubitemid 47094707)
93. Wickremasinghe SS, Michalova K, Gilhotra J, et al. Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008;115:1911-15.
94. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-7. (Pubitemid 350167096)
95. Yoon JU, Kim YM, Lee SJ, et al. Prognostic factors for visual outcome after intravitreal anti-vegf injection for naive myopic choroidal neovascularization. Retina 2012;32:949-55.
96. Zhang H, Liu ZL, Sun P, et al. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial. Am J Opthalmol 2012;153:300-6.
97. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013;382:1258-67.
98. Campbell RJ, Sudeep SG, Bronskill SE, et al. Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study. BMJ 2012;345:e4203.
99. Kelly SP, Barua A. A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medications. Eye 2011;25:710-16.
100. Shojania KG, Sampson M, Ansari MT, et al. How quickly do systematic reviews go out of date? Ann Intern Med 2007;147:224-33. (Pubitemid 351664578)